Search bioRxiv⌕ Search

Biology subjects

Guidetti, M.

Publications and source records attributed to Guidetti, M..

2 recordsLinked to original sources

Electric Field-Induced Destabilization and Surface Modulation of Aβ42 Fibrils in Molecular Simulations: Theoretical Implications for DC Stimulation in Alzheimer's Disease

The amyloid-{beta} peptide 42 (A{beta}42) forms fibrillar aggregates that are a hallmark of Alzheimers disease. While recent pharmacologic therapeutic strategies targeting A{beta}42 fibrils and oligomers have shown promising results, safer and more effective approaches are still needed. Non-invasive brain stimulation (NIBS) techniques such as repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS) have been increasingly explored as a possible complementary intervention, but the molecular mechanisms by which static electric fields could influence amyloid aggregation remain poorly understood. Here, we use atomistic molecular dynamics simulations to investigate the effects of static electric fields on A{beta}42 fibrils. We examine the response of an ex vivo fibril structure, with reconstructed N-terminal regions, to increasing field strengths under different structural restraint conditions. Our results show that the electric field perturbs the disordered N-terminal "fuzzy coat," altering its conformational dynamics and reducing its interactions with the fibril core. This reorganization modifies the surface properties of the fibril, potentially impairing secondary nucleation. Additionally, simulations with unrestrained fibril ends reveal increased fluctuations in core residues, particularly near the N-terminus, indicating a destabilizing effect that may hinder fibril elongation. While the field strengths used here exceed those typical of NIBS, our findings provide a molecular-level rationale for how electric fields could modulate fibril propagation and support further experimental investigations under physiologically relevant conditions. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=104 SRC="FIGDIR/small/678267v1_ufig1.gif" ALT="Figure 1"> View larger version (21K): org.highwire.dtl.DTLVardef@9b6a01org.highwire.dtl.DTLVardef@14ca26forg.highwire.dtl.DTLVardef@3c42ccorg.highwire.dtl.DTLVardef@458b4f_HPS_FORMAT_FIGEXP M_FIG C_FIG

biophysics↗

Two antagonistic microtubule targeting drugs act synergistically to kill cancer cells

Paclitaxel is a microtubule stabilizing agent and a successful drug for cancer chemotherapy inducing, however, adverse effects. To reduce the effective dose of paclitaxel, we searched for drugs which could potentiate its therapeutic effect. We have screened a chemical library and selected Carba1, a carbazolone, which exerts synergistic cytotoxic effects on tumor cells grown in vitro, when co-administrated with a low dose of paclitaxel. Carba1 targets the colchicine binding-site of tubulin and is a microtubule-destabilizing agent. The Carba1-induced modulation of microtubule dynamics increases the accumulation of fluorescent paclitaxel inside microtubules, providing a mechanistic explanation of the observed synergy between Carba1 and paclitaxel. The synergistic effect of Carba1 with paclitaxel on tumor cell viability was also observed in vivo in xenografted mice. Thus, a new mechanism favoring paclitaxel accumulation in microtubules can be transposed to in vivo mouse cancer treatments, paving the way for new therapeutic strategies combining low doses of microtubule targeting agents with opposite mechanisms of action.

cancer biology↗